<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">HJBM</journal-id><journal-title-group><journal-title>Hans Journal of Biomedicine</journal-title></journal-title-group><issn pub-type="epub">2161-8976</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/HJBM.2017.71001</article-id><article-id pub-id-type="publisher-id">HJBM-19602</article-id><article-categories><subj-group subj-group-type="heading"><subject>HJBM20170100000_10053949.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  鲑鱼降钙素PLGA微球缓释载体
  Salmon Calcitonin-Loaded PLGA Microspheres as a Sustained-Release Vehicle
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>吴</surname><given-names>瑞雪</given-names></name><xref ref-type="aff" rid="aff1"><sub>1</sub></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>复旦大学生命科学学院，上海</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>12210700161@fudan.edu.cn</email></corresp></author-notes><pub-date pub-type="epub"><day>23</day><month>01</month><year>2017</year></pub-date><volume>07</volume><issue>01</issue><fpage>1</fpage><lpage>8</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   本文制备六种不同分子量和末端基团的载鲑鱼降钙素PLGA微球(SCT-PLGA MS)，优选合适微球用于废用性骨质疏松症在骨折损伤部位缓释药物。载药微球平均粒径均为120 μm，形态圆整；包封率均高于60%，载药量约为0.5%；差示扫描量热(DSC)测试结果表明SCT包载在于PLGA微球中，并以无定形态存在；体外释放结果表明分子量为20 kDa的-COOH末端载药微球(SCT-PLGA-20 COOH MS) 40 天累积释放百分率达79%以上，具有良好的缓释作用；体外降解中SCT-PLGA-20 COOH MS pH值随时间延长下降速率高于其他微球。因此，本研究中SCT-PLGA-20 COOH MS有望用于治疗废用性骨质疏松症。 In this study, to optimize appropriate poly(d,l-lactic-co-glycolic acid) microspheres (PLGA MS) to release SCT in the treatment of disuse osteoporosis, six kinds of SCT-PLGA MS with different mo-lecular weight and terminal groups were prepared. SCT-PLGA MS had an average particle size of about 120 μm, an encapsulation efficiency of 60%, and a drug loading of 0.5%. The result of differential scanning calorimetry (DSC) evidenced that SCT had been entrapped as an amorphous form in MS matrix. For SCT-PLGA-20 COOH MS, the cumulative release was above 79% at 40 d. PH value of SCT-PLGA-20 COOH MS decreased more rapidly than that of MS with -CH3 in the degradation. In conclusion, SCT-PLGA-20 COOH MS is promising in the treatment of disuse osteoporosis.
    
  
 
</p></abstract><kwd-group><kwd>PLGA微球，鲑鱼降钙素，缓释, PLGA Microsphere</kwd><kwd> Salmon Calcitonin</kwd><kwd> Sustained Release</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>鲑鱼降钙素PLGA微球缓释载体<sup> </sup></title><p>吴瑞雪</p><p>复旦大学生命科学学院，上海</p><p>收稿日期：2017年1月3日；录用日期：2017年1月20日；发布日期：2017年1月23日</p><disp-formula id="hanspub.19602-formula1"><graphic xlink:href="http://html.hanspub.org/file/1-1530069x5_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>本文制备六种不同分子量和末端基团的载鲑鱼降钙素PLGA微球(SCT-PLGA MS)，优选合适微球用于废用性骨质疏松症在骨折损伤部位缓释药物。载药微球平均粒径均为120 μm，形态圆整；包封率均高于60%，载药量约为0.5%；差示扫描量热(DSC)测试结果表明SCT包载在于PLGA微球中，并以无定形态存在；体外释放结果表明分子量为20 kDa的-COOH末端载药微球(SCT-PLGA-20 COOH MS) 40 天累积释放百分率达79%以上，具有良好的缓释作用；体外降解中SCT-PLGA-20 COOH MS pH值随时间延长下降速率高于其他微球。因此，本研究中SCT-PLGA-20 COOH MS有望用于治疗废用性骨质疏松症。</p><p>关键词 :PLGA微球，鲑鱼降钙素，缓释</p><disp-formula id="hanspub.19602-formula2"><graphic xlink:href="http://html.hanspub.org/file/1-1530069x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2017 by author and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="http://image.hanspub.org:8080\Html/htmlimages\1-2890033x\e70a10f1-7c93-45ea-9603-062237856e4b.png" /><img src="http://image.hanspub.org:8080\Html\htmlimages\1-2890033x\e898c85e-ffc4-45c9-b817-14224a4d6960.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>老年患者尤其是绝经后妇女易出现原发性骨质疏松症。其主要表现为骨量减少，致使骨脆性增加，易发生骨折，导致其转化为废用性骨质疏松症。鲑鱼降钙素(Salmon calcitonin, SCT)可有效调节血钙水平和骨代谢，减少骨质流失 [<xref ref-type="bibr" rid="hanspub.19602-ref1">1</xref>] 。但肌肉注射或静脉注射SCT的临床效果不佳，为提高SCT 在废用性骨质疏松症的治疗效果，可以通过缓释载体递送药物到骨折损伤处。聚乳酸聚羟基乙酸(Poly(D, L-lactic-co-glycolic acid, PLGA) 生物相容性良好，在体内最终转化成二氧化碳和水排出体外，具有骨传导性和骨诱导性，并可制成长效缓释微球(Microsphere, MS)，提高多肽、疫苗、激素等生物大分子药物的生物利用率 [<xref ref-type="bibr" rid="hanspub.19602-ref2">2</xref>] 。PLGA的分子量以及末端官能团等理化性质均可显著影响MS中的药物释放和降解行为 [<xref ref-type="bibr" rid="hanspub.19602-ref3">3</xref>] 。因此，选择合适分子量和末端基团的PLGA十分重要。</p><p>本研究通过复乳法制备不同分子量和不同末端SCT-PLGA MS，考察PLGA理化性质对SCT载药量、体外释放和体外降解的影响，优选PLGA载药微球用于治疗废用性骨质疏松症。</p></sec><sec id="s4"><title>2. 方法</title><sec id="s4_1"><title>2.1. 材料</title><p>PLGA (LA:GA = 50:50)，分子量分别为20 kDa、40 kDa和60 kDa，特异性粘度分别为0.28 dl/g、0.37 dl/g和0.45 dl/g，末端基团为羧基(-COOH)和烷基(-CH<sub>3</sub>)，购自山东医疗器械研究所；SCT购自上海苏豪逸明制药有限公司；聚乙烯醇(polyvinyl alcohol, PVA) 购自Sigma-Aldrich公司；微量BCA试剂盒(Micro BCA)购自赛默飞世尔科技公司。</p></sec><sec id="s4_2"><title>2.2. SCT-PLGA MS的制备</title><p>称取0.3 g不同分子量和不同末端基团的PLGA (20 kDa-COOH、40 kDa-COOH、60 kDa-COOH、20 kDa-CH<sub>3</sub>、40 kDa-CH<sub>3</sub>和60 kDa-CH<sub>3</sub>)，加3 mL 二氯甲烷溶解，加入0.60 mL 4 mg/mL SCT溶液，超声3 min (输出功率150 W，工作2 s，间歇2 s)，形成W/O型初乳，立即将其注射到75 mL 0.06% (w/v) PVA溶液中，形成W/O/W型复乳。机械搅拌5 h使二氯甲烷完全挥发，静置，去离子水洗涤沉淀三次，冻干后4℃保存，得终产物SCT-PLGA-20 COOH MS、SCT-PLGA-40 COOH MS、SCT-PLGA-60 COOH MS、SCT-PLGA-20 CH<sub>3 </sub>MS、SCT-PLGA-40 CH<sub>3</sub> MS和SCT-PLGA-60 CH<sub>3</sub> MS。对照组加入与SCT溶液等体积的蒸馏水得未载药PLGA微球(blank-PLGA MS)。<sub> </sub></p></sec><sec id="s4_3"><title>2.3. SCT载药量和包封率</title><sec id="s4_3_1"><title>2.3.1. 标准曲线</title><p>按照Micro BCA试剂盒说明制备标准曲线。配制2 mg/mL的SCT溶液，精密量取50 μL，加入DDW稀释至0.5 mL，制得浓度为200 μg/mL贮备液。依次稀释，得浓度分别为40、20、10、5、2.5、1和0.5 μg/mL的SCT标准液，DDW作为空白对照。</p><p>以25:24:1(v/v/v)混合溶液A、B和C，配制Micro BCA工作液。吸取150 μL标准液，加入150 μL工作液，37℃温育2 h，量取200 μL，酶标仪测定562 nm处吸光值，以吸光值(A)对SCT浓度(C, μg/mL)线性回归，制备标准曲线。</p></sec><sec id="s4_3_2"><title>2.3.2. SCT载药量和包封率</title><p>外水相法测定SCT-PLGA微球的载药量与包封率。制备SCT-PLGA MS，洗涤前，量取3 mL悬液，13,000 rpm离心3 min，取150 μL上清液，Micro BCA法测定562 nm处吸光值，由标准曲线计算SCT浓度。分别按下列公式计算载药量(Loading Capacity, LC)和包封率(Encapsulation Efficiency, EE)：</p><disp-formula id="hanspub.19602-formula3"><graphic xlink:href="http://html.hanspub.org/file/1-1530069x9_hanspub.png"  xlink:type="simple"/></disp-formula><disp-formula id="hanspub.19602-formula4"><graphic xlink:href="http://html.hanspub.org/file/1-1530069x10_hanspub.png"  xlink:type="simple"/></disp-formula><p>其中W、W<sub>0</sub>和W<sub>1</sub>分别表示PLGA质量、SCT总质量和上清液中SCT质量。</p></sec></sec><sec id="s4_4"><title>2.4. SCT-PLGA MS的表征</title><sec id="s4_4_1"><title>2.4.1. 粒径和跨距</title><p>将微球置于载玻片上，光学显微镜观察微球，计数300个，采用系统软件测量微球的平均粒径并计算D<sub>10</sub>、D<sub>50</sub>和D<sub>90</sub>。D<sub>10</sub>、D<sub>50</sub>和D<sub>90</sub>分别表示有10%、50%和90%的微球粒径小于该值所示的粒径。</p></sec><sec id="s4_4_2"><title>2.4.2. 扫描电子显微镜 (SEM)</title><p>将少量SCT-PLGA MS固定于铝质圆台，喷金，SEM观察，加速电压20 kV。</p></sec><sec id="s4_4_3"><title>2.4.3. 差示扫描量热 (DSC)</title><p>空铝坩埚为参比，另一铝坩埚中放入精密称重后的PLGA(20 COOH)、SCT、SCT-PLGA-20 COOH MS、SCT与blank-PLGA-20 COOH MS物理混合物(5~6 mg)，扫描范围为0~200℃，升温速度为10℃/min，氮气流速为30 mL/min。</p></sec></sec><sec id="s4_5"><title>2.5. SCT-PLGA MS的体外释放</title><p>称取30 mg SCT-PLGA MS (20 COOH、40 COOH、60 COOH、20 CH<sub>3</sub>、40 CH<sub>3</sub>和60 CH<sub>3</sub>)，置离心管中，加入2 mL 0.2 mol/L PBS缓冲液(pH 7.4，含0.06% (w/v) NaN<sub>3</sub>)，37℃下以100 rpm恒温振荡，分别于1、3、7、10、15、20、23、26、30、33、36和40 d取样，并以2 mL PBS更换释放介质，继续温育。释放样品13,300 rpm离心3 min，量取上清液150 μL，Micro BCA法测定SCT浓度，计算累积释放百分率(%)。</p></sec><sec id="s4_6"><title>2.6. SCT-PLGA MS的体外降解</title><p>称取30 mg SCT-PLGA MS (20 COOH、40 COOH、60 COOH、20 CH<sub>3</sub>、40 CH<sub>3</sub>和60 CH<sub>3</sub>)，置离心管中，加入2 mL 0.2 mol/L PBS缓冲液(pH 7.4，含0.06% (w/v) NaN<sub>3</sub>)，37℃下以100 rpm恒温振荡，分别于1、2、3、4、5、6和7周测定上清液的pH值。</p></sec></sec><sec id="s5"><title>3. 结果与讨论</title><sec id="s5_1"><title>3.1. SCT-PLGA MS的制备和表征</title><sec id="s5_1_1"><title>3.1.1. SCT-PLGA MS的制备</title><p>SCT的水溶液作为内水相在二氯甲烷溶剂中分散，超声形成W/O型初乳，在外水相PVA水溶液中分散后，机械搅拌，室温下有机溶剂二氯甲烷挥发，形成W/O/W型复乳，离心洗涤后冻干得到SCT-PLGA-20 COOH MS、SCT-PLGA-40 COOH MS、SCT-PLGA-60 COOH MS、SCT-PLGA-20 CH3 MS、SCT-PLGA-40 CH3 MS和SCT-PLGA-60 CH3 MS。</p></sec><sec id="s5_1_2"><title>3.1.2. SCT载药量和包封率</title><p>SCT标准曲线为A = 0.0118 C + 0.0834，r = 0.997。可见0.5~40 μg/mL浓度范围内吸光值(A)与SCT浓度(C, μg/mL)线性关系良好。</p><p>各组微球的载药量和包封率见表1，相同分子量的微球中，-COOH末端微球的包封率高于-CH<sub>3</sub>末端微球，这是由于SCT的pI值为10.2，水环境下SCT结构中-NH<sub>2</sub>质子化形成<inline-formula><inline-graphic xlink:href="http://html.hanspub.org/file/1-1530069x11_hanspub.png" xlink:type="simple"/></inline-formula>，PLGA的-COOH末端释放质子，以-COO<sup>−</sup>离子形式存在，可与<inline-formula><inline-graphic xlink:href="http://html.hanspub.org/file/1-1530069x12_hanspub.png" xlink:type="simple"/></inline-formula>以离子键连接，增加稳定性，提高包封率，而-CH<sub>3</sub>末端微球与SCT无离子键连接，故包封率较低；PLGA分子量对微球包封率无显著影响。各组微球载药量约0.5%~0.6%。</p></sec><sec id="s5_1_3"><title>3.1.3. 粒径</title><p>载药微球的粒径和分布见表2。微球粒径主要分布于71~226 μm，平均粒径约120 μm。文献研究表明，PLGA的黏度随分子量的增大而增加，高分子量PLGA乳化时易形成较大微滴，导致微球粒径较大 [<xref ref-type="bibr" rid="hanspub.19602-ref4">4</xref>] ，但本实验中微球的分子量和末端基团对其粒径无显著影响，可能是由合成工艺的差异引起。</p></sec><sec id="s5_1_4"><title>3.1.4. SEM</title><p>图1为SCT-PLGA MS的SEM照片，可见PLGA微球平均粒径大于100 μm，形态圆整，无明显黏连，外表面的孔洞结构是由制备过程中二氯甲烷的挥发所致。PLGA的分子量和末端基团不影响微球形态。</p></sec><sec id="s5_1_5"><title>3.1.5. DSC</title><p>图2为SCT、blank-PLGA-20 COOH MS、SCT-PLGA-20 COOH MS以及PLGA原料20kDa-COOH和SCT物理混合物的DSC图谱，可见blank-PLGA-20 COOH MS和SCT-PLGA-20 COOH MS均出现尖锐的热焓松弛吸热峰，玻璃转化温度(Tg)分别为38.82℃和36.64℃，表明SCT与PLGA间的相互作用对聚合物的Tg值有较小影响；SCT图谱中110.58℃处出现宽吸热峰，PLGA和SCT物理混合物图谱中98.13℃处出现SCT的吸热峰，而SCT-PLGA-20 COOH MS中未见该吸热峰，表明SCT不是吸附于微球表面，而是包载于微球中，并以无定形态存在 [<xref ref-type="bibr" rid="hanspub.19602-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.19602-ref6">6</xref>] 。</p></sec></sec><sec id="s5_2"><title>3.2. SCT-PLGA MS的体外释放</title><p>图3(A)为不同分子量和不同末端基团的SCT-PLGA MS在PBS (pH 7.4，含0.06% (w/v) NaN<sub>3</sub>)中的药物释放曲线。SCT-PLGA-20 COOH MS、SCT-PLGA-20 CH<sub>3</sub> MS、SCT-PLGA-40 COOH MS、SCT-PLGA-40 CH<sub>3</sub> MS、SCT-PLGA-60 COOH MS和SCT-PLGA-60 CH<sub>3 </sub>MS的24 h 累积释放百分比分别为54.7%、16.0%、39.0%、31.9%、28.4%和19.3%，可见各组微球释药初期存在突释。分子量相同的PLGA微球，-COOH</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Encapsulation efficiency and loading capacity of SCT for SCT-PLGA MS. Indicated values were mean &#177; SD (n = 3</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Sample</th><th align="center" valign="middle" >EE (%)</th><th align="center" valign="middle" >LC (%)</th></tr></thead><tr><td align="center" valign="middle" >SCT-PLGA-20 COOH MS</td><td align="center" valign="middle" >76.52 &#177; 0.56</td><td align="center" valign="middle" >0.59 &#177; 0.03</td></tr><tr><td align="center" valign="middle" >SCT-PLGA-20 CH3 MS</td><td align="center" valign="middle" >65.74 &#177; 3.03</td><td align="center" valign="middle" >0.55 &#177; 0.03</td></tr><tr><td align="center" valign="middle" >SCT-PLGA-40 COOH MS</td><td align="center" valign="middle" >74.99 &#177; 3.87</td><td align="center" valign="middle" >0.56 &#177; 0.03</td></tr><tr><td align="center" valign="middle" >SCT-PLGA-40 CH3 MS</td><td align="center" valign="middle" >65.08 &#177; 3.40</td><td align="center" valign="middle" >0.52 &#177; 0.03</td></tr><tr><td align="center" valign="middle" >SCT-PLGA-60 COOH MS</td><td align="center" valign="middle" >68.84 &#177; 1.34</td><td align="center" valign="middle" >0.55 &#177; 0.01</td></tr><tr><td align="center" valign="middle" >SCT-PLGA-60 CH3 MS</td><td align="center" valign="middle" >61.88 &#177; 2.79</td><td align="center" valign="middle" >0.54 &#177; 0.01</td></tr></tbody></table></table-wrap><p>表1. SCT-PLGA MS中SCT的包封率和载药量(n = 3)</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Size distribution of SCT-PLGA MS (n = 3</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Sample</th><th align="center" valign="middle" >D<sub>10</sub><sup>a</sup> (μm)</th><th align="center" valign="middle" >D<sub>50</sub><sup>b</sup> (μm)</th><th align="center" valign="middle" >D<sub>90</sub><sup>c</sup> (μm)</th><th align="center" valign="middle" >Average Size(μm)</th></tr></thead><tr><td align="center" valign="middle" >SCT-PLGA-20 COOH MS</td><td align="center" valign="middle" >76.4</td><td align="center" valign="middle" >117.1</td><td align="center" valign="middle" >195.3</td><td align="center" valign="middle" >127.7 &#177; 44.7</td></tr><tr><td align="center" valign="middle" >SCT-PLGA-20 CH<sub>3</sub> MS</td><td align="center" valign="middle" >76.1</td><td align="center" valign="middle" >117.2</td><td align="center" valign="middle" >182.4</td><td align="center" valign="middle" >123.1 &#177; 41.7</td></tr><tr><td align="center" valign="middle" >SCT-PLGA-40 COOH MS</td><td align="center" valign="middle" >86.3</td><td align="center" valign="middle" >120.4</td><td align="center" valign="middle" >173.2</td><td align="center" valign="middle" >126.4 &#177; 35.9</td></tr><tr><td align="center" valign="middle" >SCT-PLGA-40 CH<sub>3</sub> MS</td><td align="center" valign="middle" >81.3</td><td align="center" valign="middle" >118.3</td><td align="center" valign="middle" >173.1</td><td align="center" valign="middle" >124.6 &#177; 38.4</td></tr><tr><td align="center" valign="middle" >SCT-PLGA-60 COOH MS</td><td align="center" valign="middle" >82.3</td><td align="center" valign="middle" >123.2</td><td align="center" valign="middle" >187.2</td><td align="center" valign="middle" >130.8 &#177; 43.8</td></tr><tr><td align="center" valign="middle" >SCT-PLGA-60 CH<sub>3</sub> MS</td><td align="center" valign="middle" >71.1</td><td align="center" valign="middle" >124.0</td><td align="center" valign="middle" >226.1</td><td align="center" valign="middle" >136.8 &#177; 59.4</td></tr></tbody></table></table-wrap><p>表2. SCT-PLGA MS的粒径分布(n = 3)</p><p><sup>a</sup>10%的粒子其粒径小于该值；<sup>b</sup>50%的粒子其粒径小于该值；<sup> c</sup>90%的粒子其粒径小于该值；注：结果以mean &#177; SD表示，n = 3。</p><p>图1. SCT-PLGA-20 COOH MS (a)，SCT-PLGA-40 COOH MS (b)，SCT-PLGA-60 COOH MS (c)，SCT- PLGA-20 CH<sub>3</sub> MS (d)，SCT-PLGA-40 CH<sub>3</sub> MS (e)和SCT-PLGA-60 CH<sub>3</sub> MS (f)的扫描电镜照片</p><p>末端微球突释量高于-CH<sub>3</sub>末端微球。这是由于突释药物主要来自微球表面SCT的解吸附和孔壁上SCT的溶解，-COOH末端微球的蛋白吸附率高于-CH<sub>3</sub>末端微球，故突释量较大。-COOH末端微球中，释放</p><p>图2. blank-PLGA-20 COOH S (a)，SCT-PLGA-20 COOH MS (b)，SCT (c)，及PLGA和SCT的混合物(d)的DSC图谱</p><p>图3. (A) PBS缓冲液(pH 7.4，含0.06% (w/v) NaN<sub>3</sub>)，37℃条件下，不同SCT-PLGA MS中SCT的体外释放曲线(n = 3)；(B) 不同时间各种SCT-PLGA MS溶液的pH值(n = 3)</p><p>速率随分子量的增大而减小，这是由于以下两个原因：低分子量PLGA黏度低，分子间作用力较弱，药物可较快从聚合物基质中扩散 [<xref ref-type="bibr" rid="hanspub.19602-ref7">7</xref>] ；低分子量PLGA固化较快，形成较多孔隙，高孔隙度使药物扩散速率增大。-CH<sub>3</sub>末端微球中，SCT-PLGA-20 CH<sub>3</sub> MS和SCT-PLGA-60 CH<sub>3 </sub>MS释放较少，一方面由于吸附蛋白较少，另一方面可能是粒径分布较宽，大粒径微球较多，药物通过微球扩散的途径较长，导致累积释放百分率较低 [<xref ref-type="bibr" rid="hanspub.19602-ref8">8</xref>] 。释放7 d后SCT主要从孔隙中扩散，释放速率降低；20 d后释放速率增加，这是由于PLGA逐步降解，形成孔隙，且降解生成的单体易溶于介质中，导致微球的快速溶蚀，SCT释放增多 [<xref ref-type="bibr" rid="hanspub.19602-ref9">9</xref>] 。40 d时，SCT-PLGA-20 COOH MS、SCT-PLGA-20 CH<sub>3 </sub>MS、SCT-PLGA-40 COOH MS、SCT-PLGA-40 CH<sub>3</sub> MS、SCT-PLGA-60 COOH MS和SCT-PLGA-60 CH<sub>3</sub> MS的累积释放百分比分别为85.4%、44.3%、79.6%、63.0%、70.1%和59.0%，表明本研究制备的SCT-PLGA MS具有良好的缓释效果，其中-COOH末端微球较-CH<sub>3</sub>末端微球释放更完全，SCT-PLGA-20 COOH MS 释放较理想。</p></sec><sec id="s5_3"><title>3.3. SCT-PLGA MS的体外降解</title><p>PLGA微球的体外降解对SCT的体外释放有重要影响，体外降解越快释药速率越大，释药越多。PLGA降解产物为酸性较强的LA和GA。图3(B)为随降解时间延长不同分子量和不同末端基团的SCT-PLGA MS溶液pH的变化曲线。第3周时，SCT-PLGA-20 COOH MS、SCT-PLGA-20 CH<sub>3</sub> MS、SCT-PLGA-40 COOH MS、SCT-PLGA-40 CH<sub>3</sub> MS、SCT-PLGA-60 COOH MS和SCT-PLGA-60 CH<sub>3 </sub>MS 溶液的pH值分别降至5.14、7.08、5.87、6.59、6.42和6.48，表明SCT-PLGA-20 COOH MS的降解速率最快。降解初期，聚合物发生水合作用，水性介质首先渗透到PLGA内部，使聚合物结构松散 [<xref ref-type="bibr" rid="hanspub.19602-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.19602-ref11">11</xref>] 。-COOH末端微球亲水性强，摄取水分多，故PLGA骨架降解较快，而-CH<sub>3</sub>末端微球亲水性弱，摄取水分少，PLGA骨架降解缓慢 [<xref ref-type="bibr" rid="hanspub.19602-ref12">12</xref>] 。3周后，各组微球pH下降速率增大，这是由于聚合物开始水解，PLGA分子量逐渐减小，机械强度下降。随后PLGA的链状结构被破坏，更多的介质渗透进入微球，PLGA降解为水溶性单体，暴露更多羧基，导致pH值下降。如内部的降解产物未及时扩散到外部环境中，会引起微球内部pH局部降低，引发“自催化效应” [<xref ref-type="bibr" rid="hanspub.19602-ref13">13</xref>] 。第7周时，各组pH值分别为3.22、3.33、3.04、3.26、3.43和3.57，较接近，表明PLGA MS已接近完全降解。</p></sec></sec><sec id="s6"><title>4. 结论</title><p>复乳法合成SCT-PLGA MS，平均粒径大于120 μm，形态圆整；SCT-PLGA-20 COOH MS虽突释显著，但累积释放量较高，体外降解迅速，有望用于治疗废用性骨质疏松症。</p></sec><sec id="s7"><title>致谢</title><p>感谢指导过和帮助过本研究的老师和师长。</p></sec><sec id="s8"><title>文章引用</title><p>吴瑞雪. 鲑鱼降钙素PLGA微球缓释载体 Salmon Calcitonin-Loaded PLGA Microspheres as a Sustained-Release Vehicle[J]. 生物医学, 2017, 07(01): 1-8. http://dx.doi.org/10.12677/HJBM.2017.71001</p></sec><sec id="s9"><title>参考文献 (References)</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.19602-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Glowka, E., Sapin-Minet, A., Leroy, P., et al. (2010) Preparation and in Vitro-in Vivo Evaluation of Salmon Calcitonin-Loaded Polymeric Nanoparticles. Journal of Microencapsulation, 27, 25-36.  
&lt;br&gt;https://doi.org/10.3109/02652040902751125</mixed-citation></ref><ref id="hanspub.19602-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, Z., Kuijer, R., Bulstra, S.K., et al. (2006) The in Vivo and in Vitro Degradation Behavior of Poly(trimethylene carbonate). Biomaterials, 27, 1741-1748. &lt;br&gt;https://doi.org/10.1016/j.biomaterials.2005.09.017</mixed-citation></ref><ref id="hanspub.19602-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Roy, A., Jhunjhunwala, S., Bayer, E., et al. (2016) Porous Calcium Phosphate-Poly (Lactic-Co-Glycolic) Acid Composite Bone Cement, a Viabe Tunable Drug Delivery System. Materials Science and Engineering C, 59, 92-101.  
&lt;br&gt;https://doi.org/10.1016/j.msec.2015.09.081</mixed-citation></ref><ref id="hanspub.19602-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Cai, C., Mao, S., Germershaus, O., et al. (2009) Influence of Morphology and Drug Distribution on the Release Process of FITC-Dextran-Loaded Microspheres Prepared with Different Types of PLGA. Journal of Microencapsulation, 26, 334-345. &lt;br&gt;https://doi.org/10.1080/02652040802354707</mixed-citation></ref><ref id="hanspub.19602-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Tzeng, C.W., Yen, F.L., Wu, T.H., et al. (2011) Enhancement of Dissolution and Antioxidant Activity of Kaempferol Using a Nanoparticle Engineering Process. Journal of Agricultural and Food Chemistry, 59, 5073-5080.  
&lt;br&gt;https://doi.org/10.1021/jf200354y</mixed-citation></ref><ref id="hanspub.19602-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Cheng, W.P., Thompson, C., Ryan, S.M., et al. (2010) In Vitro and in Vivo Characterisation of a Novel Peptide Delivery System, Amphiphilic Polyelectrolyte-Salmon Calcitonin Nanocomplexes. Journal of Controlled Release, 147, 289-297. &lt;br&gt;https://doi.org/10.1016/j.jconrel.2010.07.128</mixed-citation></ref><ref id="hanspub.19602-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Liu, Q., Zhang, H., Zhou, G., et al. (2010) In Vitro and in Vivo Study of Thymosin Alpha1 Biodegradable in Situ Forming Poly(lactide-co-glycolide) Implants. International Journal of Pharmaceutics, 397, 122-129.  
&lt;br&gt;https://doi.org/10.1016/j.ijpharm.2010.07.015</mixed-citation></ref><ref id="hanspub.19602-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Diaz, R.V., Llabrés, M. and Evora, C. (1999) One-Month Sustained Release Microspheres of I-125-Bovine Calcitonin-In Vitro-in Vivo Studies. Journal of Controlled Release, 59, 55-62.  
&lt;br&gt;https://doi.org/10.1016/S0168-3659(98)00179-5</mixed-citation></ref><ref id="hanspub.19602-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Giovagnoli, S., Blasi, P., Ricci, M., et al. (2004) Biodegradable Microspheres as Carriers for Native Superoxide Dismutase and Catalase Delivery. AAPS PharmSciTech, 5, e51. &lt;br&gt;https://doi.org/10.1208/pt050451</mixed-citation></ref><ref id="hanspub.19602-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Ghalanbor, Z., Körber, M. and Bodmeier, R. (2013) Interdependency of Protein-Release Completeness and Polymer Degradation in PLGA-Based Implants. European Journal of Pharmaceutics and Biopharmaceutics, 85, 624-630.  
&lt;br&gt;https://doi.org/10.1016/j.ejpb.2013.03.031</mixed-citation></ref><ref id="hanspub.19602-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Selmin, F., Blasi, P., and De Luca, P.P. (2012) Accelerated Polymer Biodegradation of Risperidone Poly (D,L-lactide-co-glycolide) Microspheres. AAPS PharmSciTech, 13, 1465-1472.  
&lt;br&gt;https://doi.org/10.1208/s12249-012-9874-4</mixed-citation></ref><ref id="hanspub.19602-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Samadi, N., Abbadessa, A., Di Stefano, A., et al. (2013) The Effect of Lauryl Capping Group on Protein Release and Degradation of Poly(D,L-lactic-co-glycolic acid) Particles. Journal of Controlled Release, 172, 436-443.  
&lt;br&gt;https://doi.org/10.1016/j.jconrel.2013.05.034</mixed-citation></ref><ref id="hanspub.19602-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Sawamura, T., Mizutani, Y., Okuyama, M., et al. (2014) Setting Time and Formability of Calcium Phosphate Cements Prepared Using Modified Dicalcium Phosphate Anhydrous Powders. Journal of Materials Science Materials in Medicine, 25, 1631-1636. &lt;br&gt;https://doi.org/10.1007/s10856-014-5209-1</mixed-citation></ref></ref-list></back></article>